Physician profile
Frampton W Henderson
NPI 1407802184
$7,290.12
in general payments reported to CMS, 2019-2025
50 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $1,111 · 2021: $1,226 · 2022: $922 · 2023: $1,126 · 2024: $1,027 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,879.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $817.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $816.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $728.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $455.64 | 2019-2025 | |
| Amgen INC. | $356.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $353.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $341.57 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $318.61 | 2021-2024 | |
| Abbott Laboratories | $281.98 | 2020-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $261.32 | 2019-2021 | |
| Abbvie INC. | $250.21 | 2019-2025 | |
| Dexcom, INC. | $237.70 | 2021-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.66 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $204.28 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $160.06 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frampton Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.